CD8+ T Cell Mediated Disease
Our overall aim is to understand the mechanisms of CD8+ T-cell mediated disease and use this knowledge to develop novel therapeutic reagents.
Our interests include:
The role of CD8+ T cells in autoimmune disease: It is emerging that CD8+ T cells play a major role in the pathogenesis of autoimmune diseases such as Type I diabetes and multiple sclerosis. In collaboration with Professor Neil Robertson we are examining CD8+ T cell responses in multiple sclerosis patients and identifying their antigenic targets.
T cell leukaemia: Although rare, some leukaemia’s are characterised by significant monoclonal CD8+ T cell expansions. We are interested in determining the factors that trigger these expansions and also how to treat these conditions.
Alloreactivity: We are in the process of adapting our ligand identification technology so that we can identify ligands that drive alloreactive CD8+ T cell responses which are beneficial in destroying tumour cells (GvHD). In the future, we also hope that this work will lead to a better understanding of the mechanisms that underlie transplant rejection.